Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma-Reference-Cited by-同舟云学术

Copper 64–labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

Published:2018-02-15 Issue:7 Volume:131 Page:741-745
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Caserta Enrico¹²,Chea Junie³,Minnix Megan³,Poku Erasmus K.³,Viola Domenico¹²,Vonderfecht Steven⁴,Yazaki Paul³,Crow Desiree³,Khalife Jihane¹²,Sanchez James F.²,Palmer Joycelynne M.⁵,Hui Susanta⁶,Carlesso Nadia¹,Keats Jonathan⁷,Kim Young⁸,Buettner Ralf²,Marcucci Guido¹,Rosen Steven²,Shively John³,Colcher David³,Krishnan Amrita²,Pichiorri Flavia¹²

Affiliation:

1. Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope, Duarte, CA;

2. Briskin Myeloma Center, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA;

3. Department of Molecular Immunology and

4. Center for Comparative Medicine, Beckman Research Institute, City of Hope, Duarte, CA;

5. Department of Information Sciences, Division of Biostatistics, City of Hope, Duarte, CA;

6. Department of Radiation Oncology, Beckman Research Institute, City of Hope, Duarte, CA;

7. Translational Genomics Research Institute, Phoenix, AZ; and

8. Department of Pathology, City of Hope, Duarte, CA

Abstract

Key Points Daratumumab conjugated with 64Cu efficiently binds to CD38 on myeloma cells and was mainly detected in the bones of mice. PET/CT based on 64Cu-radiolabeled daratumumab displays a higher resolution and specificity for detecting myeloma than does 18F-FDG PET/CT.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/131/7/741/1406952/blood807263.pdf

Reference26 articles.

1. The treatment of relapsed and refractory multiple myeloma;Richardson;Hematology Am Soc Hematol Educ Program,2007

2. Clinically relevant end points and new drug approvals for myeloma;Anderson;Leukemia,2008

3. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma;Bartel;Blood,2009

4. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation;Zamagni;Blood,2011

5. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease;Zamagni;Leukemia,2016

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PET Imaging in Chimeric Antigen Receptor T-Cell Trafficking;PET Clinics;2024-10

2. New PET Tracers for Symptomatic Myeloma;PET Clinics;2024-10

3. Expanding horizons in cancer therapy by immunoconjugates targeting tumor microenvironments;Critical Reviews in Oncology/Hematology;2024-09

4. Development of New CD38 Targeted Peptides for Cancer Imaging;Molecular Imaging and Biology;2024-03-13

5. CD38‐Specific Gallium‐68 Labeled Peptide Radiotracer Enables Pharmacodynamic Monitoring in Multiple Myeloma with PET;Advanced Science;2024-02-29